Haemostasis and Therapeutic Hypothermia

Is Haemostasis Impaired in Cardiac Arrest Patients During Therapeutic Hypothermia?

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02179021

Enrollment

Registered

2014-07-01

Start date

2014-01-31

Completion date

2015-05-31

Last updated

2015-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Arrest, Hypothermia

Keywords

Thromboelastometry, Haemostasis, Hypothermia, Heart arrest

Brief summary

The purpose of this study is to investigate, if the haemostasis is impaired in cardiac arrest patients during therapeutic hypothermia compared with normothermia.

Detailed description

Treatment with mild therapeutic hypothermia, 32-34 °C for 12-24 hours, has shown to improve the neurologic outcome in comatose survivors of out-of-hospital cardiac arrest. Hypothermia is suspected to inhibit haemostasis and therefore cardiac arrest patients with a risk of bleeding are not treated with therapeutic hypothermia. However, the impact on the coagulation system during mild therapeutic hypothermia, has not yet been fully investigated. The investigators aim to investigate if mild therapeutic hypothermia influences haemostasis. We are including survivors of cardiac arrest, who are treated with hypothermia for 24-48 hours. Blood will be sampled during hypothermia and secondly during normothermia. 30 minutes after the blood are sampled it will be analyzed using a sensitive low-tissue-factor assay with rotational thromboelastometry (ROTEM®). All the dynamic coagulation parameters obtained on the ROTEM® at hypothermia and normothermia, respectively, will be compared.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Treatment with therapeutic hypothermia, for minimum 24 and up to 48 hours, due to cardiac arrest.

Exclusion criteria

* age \<18 years.

Design outcomes

Primary

Measure	Time frame	Description
To detect changes in clotting time in seconds (s), during the first 3 days after target temperature (34 °C) is reached.	22, 46 and 70 hours after target temperature (34 °C) is reached (+/- 2 hours).	Clotting time will be measured by thromboelastometry on the ROTEM-analyzer using a low-tissue-factor assay.

Secondary

Measure	Time frame	Description
To detect changes in the clot formation time (s), during the first 3 days after target temperature (34 °C) is reached.	22, 46 and 70 hours after target temperature (34 °C) is reached (+/- 2 hours).	Coagulation parameters will be measured by thromboelastometry on the ROTEM® using a low-tissue-factor assay.
To detect changes in maximum clot firmness (mm), during the first 3 days after target temperature (34 °C) is reached.	22, 46 and 70 hours after hypothermia is reached. (+/- 2 hours)	Coagulation parameters will be measured by thromboelastometry on the ROTEM® using a low-tissue-factor assay.
To detect changes in time to maximum velocity (s), during the first 3 days after target temperature (34 °C) is reached.	22, 46 and 70 hours after target temperature (34 °C) is reached (+/- 2 hours).	Coagulation parameters will be measured by thromboelastometry on the ROTEM® using a low-tissue-factor assay.
To detect changes in maximum velocity (mm/min.), during the first 3 days after target temperature (34 °C) is reached.	22, 46 and 70 hours after target temperature (34 °C) is reached (+/- 2 hours).	Coagulation parameters will be measured by thromboelastometry on the ROTEM® using a low-tissue-factor assay.

Countries

Denmark

Outcome results